Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
| Revenue (Most Recent Fiscal Year) | $398.20M |
| Net Income (Most Recent Fiscal Year) | $71.41M |
| PE Ratio (Current Year Earnings Estimate) | 8.13 |
| PE Ratio (Trailing 12 Months) | 17.96 |
| PEG Ratio (Long Term Growth Estimate) | 0.81 |
| Price to Sales Ratio (Trailing 12 Months) | 4.37 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.16 |
| Pre-Tax Margin (Trailing 12 Months) | 23.73% |
| Net Margin (Trailing 12 Months) | 17.93% |
| Return on Equity (Trailing 12 Months) | 26.56% |
| Return on Assets (Trailing 12 Months) | 22.13% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 4.54 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.49 |
| Earnings per Share (Most Recent Fiscal Year) | $1.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.61 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 118.01M |
| Free Float | 103.73M |
| Market Capitalization | $1.74B |
| Average Volume (Last 20 Days) | 1.31M |
| Beta (Past 60 Months) | 0.89 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 79.22% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |